News
When treating patients with hormone-receptor positive, HER2-negative metastatic breast cancer, mutations necessitate the ...
Data from the CEPHEUS trial support the use of D-VRd in patients with transplant-ineligible or -deferred multiple myeloma who can tolerate bortezomib. Adding daratumumab (Darzalex) to bortezomib ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback